Market
First Region to Approve Merck's HS-10535 by End of 2026?
2
Resolution / Starting Odds
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Regulatory announcements from respective health authorities
Story
Merck Acquires Rights to HS-10535, a Chinese GLP-1 Receptor Agonist, in $2 Billion Deal with Hansoh Pharma
Dec 18, 2024, 11:58 AM
Merck & Co. Inc. has entered into an exclusive global license agreement with Hansoh Pharma, a Chinese biopharmaceutical company, to develop, manufacture, and commercialize HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. The agreement includes an upfront payment of $112 million to Hansoh Pharma, with the potential for up to $1.9 billion in milestone payments related to the development, regulatory approval, and commercialization of the drug, along with royalties on sales. Merck aims to leverage this agreement to enhance its pipeline and explore the potential of HS-10535 to provide cardiometabolic benefits beyond weight reduction. Hansoh Pharma may co-promote or solely commercialize the drug in China under certain conditions.
View original story
Similar markets
United States • 25%
China • 25%
European Union • 25%
Other • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
European Union • 25%
Africa • 25%
Asia • 25%
North America • 25%
Europe • 25%
Africa • 25%
European Union • 25%
United States • 25%
Other • 25%
Other • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
European Union • 25%
Japan • 25%
Canada • 25%
European Union • 25%
United States • 25%
Asia-Pacific • 25%
Other regions • 25%
Multiple continents • 25%
United States only • 25%
United States and EU countries • 25%
United States and Asian countries • 25%